In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program

DOI: 10.1128/AAC.00169-18

Article Information

DOI

PubMed

Published By

History

^aInternational Health Management Associates, Inc., Schaumburg, Illinois, USA
^bDepartment of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
^cMerck & Co., Inc., Kenilworth, New Jersey, USA

Address correspondence to Sibylle H. Lob, shlob{at}ihma.com.
Citation Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. 2018. In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program. Antimicrob Agents Chemother 62:e00169-18. https://doi.org/10.1128/AAC.00169-18.

Rendering graph...